A Phase 2 Study of a Human Anti-PDGFR-alpha Monoclonal Antibody (IMC-3G3) in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors (GIST).
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Olaratumab (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 14 Feb 2017 Results published in the Annals of Oncology.
- 27 Jan 2017 Status changed from completed to discontinued.
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.